Leptomeningeal disease from melanoma—Poor prognosis despite new therapeutic modalities
European Journal of Cancer2021Vol. 148, pp. 395–404
Citations Over TimeTop 10% of 2021 papers
Eleftheria Chorti, Sied Kebir, Misbah S. Ahmed, Kathy Keyvani, Lale Umutlu, Theodora Kanaki, Anne Zaremba, Finja Reinboldt-Jockenhoefer, Sarah Knispel, Emmanouil Gratsias, Alexander Roesch, Selma Ugurel, Björn Scheffler, Dirk Schadendorf, Elisabeth Livingstone, Friedegund Meier, Martin Glas, Lisa Zimmer
Related Papers
- → Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study(2021)4 cited
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer(2012)
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)